EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective

Abstract

Authors

T Liu M Purser C Gong D Elsea N Niehoff E Dlotko K. Migliaccio-Walle Y Samyshkin

Full Text Cite This Article
Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×